A Magnetic Modulation Biosensing-Based Molecular Assay for Rapid and Highly Sensitive Clinical Diagnosis of Coronavirus Disease 2019 (COVID-19)

Margulis, Michael; Erster, Oran; Roth, Shira; Mandelboim, Michal; Danielli, Amos

doi:10.1016/j.jmoldx.2021.08.012

Cited by 12 publications

(20 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to identify coronavirus patients, nasopharyngeal and oropharyngeal swab samples were collected for RT-PCR testing. Currently, the gold standard test for SARS-CoV-2-specific ribonucleic acid (RNA) is based on the reverse transcription quantitative polymerase chain reaction (RT-qPCR), which relies on target amplification by Taq polymerase and uses a fluorescent resonance energy transfer (FRET)-based hydrolysis probe (11). Patient characteristics.…”

Section: Methodsmentioning

confidence: 99%

Impact of the COVID-19 Pandemic on Treatment and Oncologic Outcomes for Cancer Patients in Romania

Trifănescu

Galeş

Bacinschi

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: This study aimed to assess the impact of the ongoing COVID-19 pandemic on cancer patients, known to be immune-compromised due to the disease itself, oncological treatments and adjuvant medicines use such as steroids. Overall survival was determined for patients with COVID-19 infection and stratification according to known comorbidities and complications was performed. Patients and Methods: This prospective study included ninety cancer patients with COVID-19 confirmed by PCR testing performed before each cycle of chemotherapy or every two weeks during radiotherapy between May and December 2020 in two tertiary Cancer Centers. Demographic, cancer-related and SARS-CoV-2 infection data were collected and long-term oncologic outcome was assessed. Results: Mean age of cancer patients diagnosed with SARS-CoV-2 was 59.7±12.1 years (range=30-83 years). Fifty-two (57.7%) were women. The most frequent cancer localization was breast (n=28, 31.1%) followed by colorectal (n=11, 12.2%) and lung cancer (n=8, 8.8%). Most patients infected with SARS-CoV-2 were diagnosed in stage IV of the disease (n=44, 48.9%) followed by stage III (n=19, 21.1%) and stage II disease (18.9%). Regarding comorbidities, the most common was hypertension (n=31) followed by cardiac dysfunction (n=23) and type II diabetes (n=13). Of 27 (30%) patients who needed hospitalization, 4 patients developed severe infection, 17 patients had mild symptoms and 6 patients were minimally symptomatic. After a median follow-up of 22.5 months, 5 patients (5.55%) died due to SARS-COV-2 infection, all stages III and IV. Median estimated overall survival was 14 months in patients who died because of COVID infection compared to 98 months in cancer-related mortality analysis (p<0.0001). Three deaths occurred during chemotherapy, 1 death in the chemoradiotherapy radiotherapy group. Conclusion: SARS-CoV-2 infection was associated with an excess mortality in our study population, especially in patients with advanced and metastatic disease and in those receiving immunosuppressive treatment such as chemotherapy and radiotherapy.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting illness, COVID-19, have emerged as a global pandemic (1). In 2003, the SARS epidemic was correlated with a coronavirus. The new coronavirus (2019-nCoV), first appeared in December 2019 in Wuhan (China) as the perpetuator of severe respiratory infection in humans (2). The World Health Organization (WHO) made the assessment that COVID-19 must be defined and treated as a pandemic in March 2020. The human coronavirus disease COVID-19 became the fifth registered pandemic sequent to the 1918 Spanish flu, 1957 Asian flu, 1968 Hong Kong flu and the 2009 Pandemic flu (3). In September 2021, the total number of confirmed cases of SARS-CoV-2 infection was 229,222,879 worldwide. The total number of deaths allocated to this disease was 4,702,936. Some countries did not compile this data and many recoveries from both confirmed and untested infections remain unregistered. Unfortu...

show abstract

Section: Methodsmentioning

confidence: 99%

Impact of the COVID-19 Pandemic on Treatment and Oncologic Outcomes for Cancer Patients in Romania

Trifănescu

Galeş

Bacinschi

et al. 2022

In Vivo

View full text Add to dashboard Cite

show abstract

“…Using a modified double-quenched hydrolysis probe, we developed an MMB-based molecular assay for rapid (<30 min) detection of SARS-CoV-2 nucleic acid targets (Figure 12) [60].…”

Section: Detecting Low Abundance Nucleic Acid Targetsmentioning

confidence: 99%

Section: Detecting Low Abundance Nucleic Acid Targetsmentioning

confidence: 99%

“…Using a modified double-quenched hydrolysis probe, we developed an MMB-based molecular assay for rapid (<0 min) detection of SARS-CoV-2 nucleic acid targets (Figure 12) [60]. The short turnaround time of the assay is achieved by reducing the number of amplification cycles to 40 and reducing the duration of each amplification cycle to 23 s (compared to 90 s in regular RT-qPCR).…”

Section: Detecting Low Abundance Nucleic Acid Targetsmentioning

confidence: 99%

“…To produce a dose response curve for the MMB-based SARS-CoV-2 molecular assay, we used in vitro transcribed SARS-CoV-2 targets (Figure 13a). The calculated LoD was 1.6 target copies per reaction, which is equivalent to 0.32 RNA copies/µL [60]. The MMB-based molecular assay was validated by blind-testing 309 clinical samples, of which 139 were collected from verified COVID-19 patients and 170 from SARS-CoV-2-negative individuals.…”

Section: Detecting Low Abundance Nucleic Acid Targetsmentioning

confidence: 99%

See 2 more Smart Citations

Recent Advances in Rapid and Highly Sensitive Detection of Proteins and Specific DNA Sequences Using a Magnetic Modulation Biosensing System

Roth

Margulis

Danielli

2022

Sensors

Self Cite

View full text Add to dashboard Cite

In early disease stages, biomolecules of interest exist in very low concentrations, presenting a significant challenge for analytical devices and methods. Here, we provide a comprehensive overview of an innovative optical biosensing technology, termed magnetic modulation biosensing (MMB), its biomedical applications, and its ongoing development. In MMB, magnetic beads are attached to fluorescently labeled target molecules. A controlled magnetic force aggregates the magnetic beads and transports them in and out of an excitation laser beam, generating a periodic fluorescent signal that is detected and demodulated. MMB applications include rapid and highly sensitive detection of specific nucleic acid sequences, antibodies, proteins, and protein interactions. Compared with other established analytical methodologies, MMB provides improved sensitivity, shorter processing time, and simpler protocols.

show abstract

Recent progress on rapid diagnosis of COVID-19 by point-of-care testing platforms

Tang

Jiang

Wang

et al. 2024

Chinese Chemical Letters

View full text Add to dashboard Cite

A Magnetic Modulation Biosensing-Based Molecular Assay for Rapid and Highly Sensitive Clinical Diagnosis of Coronavirus Disease 2019 (COVID-19)

Cited by 12 publications

References 26 publications

Impact of the COVID-19 Pandemic on Treatment and Oncologic Outcomes for Cancer Patients in Romania

Impact of the COVID-19 Pandemic on Treatment and Oncologic Outcomes for Cancer Patients in Romania

Recent Advances in Rapid and Highly Sensitive Detection of Proteins and Specific DNA Sequences Using a Magnetic Modulation Biosensing System

Recent progress on rapid diagnosis of COVID-19 by point-of-care testing platforms

Contact Info

Product

Resources

About